July 2026 in “Frontiers in Medicine” A new treatment plan for alopecia areata considers disease severity, quality of life, and progression to offer personalized care.
October 2010 in “Informa Healthcare eBooks”
The new gel for hair loss is safe, effective, and reduces side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
October 2011 in “Iranian Journal of Dermatology” Men with male pattern baldness may have a higher risk of heart disease due to increased levels of a specific lipid in their blood.
1 citations
,
January 2023 Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.
1 citations
,
November 2025 in “Journal of the American Academy of Dermatology” March 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Low levels of zinc and ferritin may worsen alopecia areata.
August 2023 in “Journal of The American Academy of Dermatology” Finasteride made hair thicker on the back of the head in men with hair loss.
April 2019 in “International research journal of pharmacy” Adiantum capillus extract reduces pain and swelling in animals.
11 citations
,
April 1997 in “International Journal of Dermatology” Using tretinoin with triamcinolone acetonide helps treat alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
3 citations
,
April 2024 in “International Journal of Women’s Dermatology” Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Poor air quality increases the risk of atopic dermatitis in Taiwan.
July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
January 2026 in “Zagazig University Medical Journal”
7 citations
,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
4 citations
,
March 2017 in “Al-Mi’galaẗ al-sa'udiyaẗ lī-ulum al-ḥayaẗ” Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
January 2026 in “Egyptian Journal of Dermatology and Venerology” Androgenetic alopecia is linked to insulin resistance and hormonal imbalances.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.